Aliskiren induced remarkable hypertriglyceridemia

Intern Med. 2012;51(24):3387-9. doi: 10.2169/internalmedicine.51.8567. Epub 2012 Dec 15.

Abstract

We herein report the first case of remarkable hypertriglyceridemia induced by aliskiren. A 42-year-old man with chronic kidney disease who had been taking antihypertensive medication for approximately 10 years was treated with aliskiren at a dose of 150 mg/day due to uncontrolled hypertension. Six weeks later, although the patient's blood pressure decreased, a laboratory examination revealed remarkable hypertriglyceridemia and an elevated creatinine level. We suspected the occurrence of an adverse event of aliskiren, and the medication was discontinued. Thereafter, the hypertriglyceridemia and elevated creatinine level spontaneously improved. Transient eosinophilia and a strong-positive response of drug lymphocyte stimulation test (DLST) to aliskiren occurred during the patient's clinical course, and we determined the remarkable hypertriglyceridemia to be an adverse event of aliskiren.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Amides / adverse effects*
  • Antihypertensive Agents / adverse effects*
  • Fumarates / adverse effects*
  • Humans
  • Hypertriglyceridemia / chemically induced*
  • Male

Substances

  • Amides
  • Antihypertensive Agents
  • Fumarates
  • aliskiren